| scholarly article | Q13442814 |
| P50 | author | Christoph Correll | Q56954221 |
| P2093 | author name string | Robert M Hamer | |
| Leslie Miller | |||
| Mark A Riddle | |||
| Marina Spanos | |||
| Linmarie Sikich | |||
| Gloria Reeves | |||
| Jacqueline Johnson | |||
| Courtney Keeton | |||
| Sarah Edwards | |||
| Sandeep Kapoor | |||
| Irmgard Borner | |||
| Shauna P Reinblatt | |||
| Kristin Bussell | |||
| Tara Chandrasekhar | |||
| Abigail Scheer | |||
| Cheryl Alderman | |||
| Sara Pirmohamed | |||
| Terrence C Bethea | |||
| Eva M Sheridan | |||
| P2860 | cites work | The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials | Q61451863 |
| Lifestyle Interventions for Weight Management in People with Serious Mental Illness: A Systematic Review with Meta-Analysis, Trial Sequential Analysis, and Meta-Regression Analysis Exploring the Mediators and Moderators of Treatment Effects | Q90110969 | ||
| The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness | Q92032782 | ||
| Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems | Q24235450 | ||
| Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935 | Q28155804 | ||
| A rating scale for drug-induced akathisia | Q28258433 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data | Q29616031 | ||
| Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: A systematic review and meta-analysis. | Q30251465 | ||
| Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls | Q33670588 | ||
| Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality | Q33694959 | ||
| The clinical global impressions scale: applying a research tool in clinical practice | Q33894649 | ||
| Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents | Q34613195 | ||
| Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. | Q34631699 | ||
| Childhood body-mass index and the risk of coronary heart disease in adulthood | Q34710887 | ||
| Defining clinical phenotypes of juvenile mania | Q35075420 | ||
| Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics | Q35641776 | ||
| Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology | Q35963737 | ||
| Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis | Q36118736 | ||
| Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis | Q37015327 | ||
| The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesi | Q37015355 | ||
| Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report | Q37022782 | ||
| Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes | Q37050190 | ||
| A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | Q37172973 | ||
| Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods | Q37354917 | ||
| Metabolic and cardiovascular adverse effects associated with antipsychotic drugs | Q37947095 | ||
| Insulin and the brain | Q38066536 | ||
| Effects of metformin on weight loss: potential mechanisms. | Q38238203 | ||
| Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial | Q38388473 | ||
| Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis | Q38705205 | ||
| Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist | Q38903768 | ||
| Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials | Q39660129 | ||
| Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia | Q39759690 | ||
| Metabolic Testing for Adults in a State Medicaid Program Receiving Antipsychotics: Remaining Barriers to Achieving Population Health Prevention Goals. | Q39775400 | ||
| Differential metformin dose-dependent effects on cognition in rats: role of Akt. | Q39823034 | ||
| Metabolic screening in children receiving antipsychotic drug treatment | Q43109191 | ||
| Should we rely on the Kenward-Roger approximation when using linear mixed models if the groups have different distributions? | Q43522773 | ||
| Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. | Q45023301 | ||
| Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study | Q46365535 | ||
| A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. | Q46438460 | ||
| Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long? | Q47211240 | ||
| A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder | Q47271229 | ||
| A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents | Q47310987 | ||
| Performance of a weight-related measure of Quality of Life in a psychiatric sample | Q47337805 | ||
| Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials | Q47368177 | ||
| Antipsychotic Use in Youth Without Psychosis: A Double-edged Sword | Q48079001 | ||
| Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. | Q50456515 | ||
| National trends in the mental health care of children, adolescents, and adults by office-based physicians. | Q50674398 | ||
| Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. | Q51108753 | ||
| A revised anchored version of the BPRS-C for childhood psychiatric disorders. | Q51967370 | ||
| Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. | Q52668951 | ||
| A rating scale for extrapyramidal side effects | Q53780342 | ||
| P433 | issue | 1 | |
| P921 | main subject | metformin | Q19484 |
| P304 | page(s) | 69-80 | |
| P577 | publication date | 2020-02-01 | |
| P1433 | published in | World Psychiatry | Q8036083 |
| P1476 | title | Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial | |
| P478 | volume | 19 |
Search more.